These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
373 related articles for article (PubMed ID: 10387929)
1. Uterotrophic effects of tamoxifen, toremifene, and raloxifene do not predict endometrial cell proliferation in the ovariectomized CD1 mouse. Carthew P; Edwards RE; Nolan BM Toxicol Appl Pharmacol; 1999 Jul; 158(1):24-32. PubMed ID: 10387929 [TBL] [Abstract][Full Text] [Related]
2. Compartmentalized uterotrophic effects of tamoxifen, toremifene, and estradiol in the ovariectomized Wistar (Han) rat. Carthew P; Edwards RE; Nolan BM; Tucker MJ; Smith LL Toxicol Sci; 1999 Apr; 48(2):197-205. PubMed ID: 10353311 [TBL] [Abstract][Full Text] [Related]
3. Activity of raloxifene in immature and ovariectomized rat uterotrophic assays. Ashby J; Odum J; Foster JR Regul Toxicol Pharmacol; 1997 Jun; 25(3):226-31. PubMed ID: 9237325 [TBL] [Abstract][Full Text] [Related]
4. Effects of two novel selective estrogen receptor modulators, raloxifene, tamoxifen, and ethinyl estradiol on the uterus, vagina and breast in ovariectomized cynomolgus monkeys (Macaca fascicularis). Sikoski P; Register TC; Lees CJ; Lundeen S; Hutchison J; Brown KH; Cline JM Am J Obstet Gynecol; 2007 Jan; 196(1):75.e1-7. PubMed ID: 17240242 [TBL] [Abstract][Full Text] [Related]
5. The effects of the selective estrogen receptor modulators, methyl-piperidino-pyrazole (MPP), and raloxifene in normal and cancerous endometrial cell lines and in the murine uterus. Davis AM; Ellersieck MR; Grimm KM; Rosenfeld CS Mol Reprod Dev; 2006 Aug; 73(8):1034-44. PubMed ID: 16688783 [TBL] [Abstract][Full Text] [Related]
6. Pharmacological actions of a novel, potent, tissue-selective benzopyran estrogen. Galbiati E; Caruso PL; Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M J Pharmacol Exp Ther; 2002 Oct; 303(1):196-203. PubMed ID: 12235251 [TBL] [Abstract][Full Text] [Related]
7. Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats. Wang XN; Simmons HA; Salatto CT; Cosgrove PG; Thompson DD Menopause; 2006; 13(4):609-20. PubMed ID: 16837883 [TBL] [Abstract][Full Text] [Related]
8. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Tomás E; Kauppila A; Blanco G; Apaja-Sarkkinen M; Laatikainen T Gynecol Oncol; 1995 Nov; 59(2):261-6. PubMed ID: 7590484 [TBL] [Abstract][Full Text] [Related]
9. Estrogen and selective estrogen receptor modulator regulation of insulin-like growth factor binding protein 5 in the rat uterus. Andrade PM; Silva ID; Borra RC; Lima GR; Baracat EC Gynecol Endocrinol; 2002 Aug; 16(4):265-70. PubMed ID: 12396554 [TBL] [Abstract][Full Text] [Related]
10. Adenomyosis--a result of disordered stromal differentiation. Parrott E; Butterworth M; Green A; White IN; Greaves P Am J Pathol; 2001 Aug; 159(2):623-30. PubMed ID: 11485920 [TBL] [Abstract][Full Text] [Related]
11. Gene expression changes induced by estrogen and selective estrogen receptor modulators in primary-cultured human endometrial cells: signals that distinguish the human carcinogen tamoxifen. Pole JC; Gold LI; Orton T; Huby R; Carmichael PL Toxicology; 2005 Jan; 206(1):91-109. PubMed ID: 15590111 [TBL] [Abstract][Full Text] [Related]
12. Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women. Marttunen MB; Cacciatore B; Hietanen P; Pyrhönen S; Tiitinen A; Wahlström T; Ylikorkala O Br J Cancer; 2001 Apr; 84(7):897-902. PubMed ID: 11286468 [TBL] [Abstract][Full Text] [Related]
13. Effects of tamoxifen and raloxifene on normal human endometrial cells in an organotypic in vitro model. Bläuer M; Heinonen PK; Rovio P; Ylikomi T Eur J Pharmacol; 2008 Sep; 592(1-3):13-8. PubMed ID: 18638473 [TBL] [Abstract][Full Text] [Related]
14. An in vivo battery for identifying endocrine modulators that are estrogenic or dopamine regulators. O'Connor JC; Cook JC; Craven SC; Van Pelt CS; Obourn JD Fundam Appl Toxicol; 1996 Oct; 33(2):182-95. PubMed ID: 8921337 [TBL] [Abstract][Full Text] [Related]
15. Upregulation of estrogen receptor expression in the uterus of ovariectomized B6C3F1 mice and Ishikawa cells treated with bromoethane. Aoyama H; Couse JF; Hewitt SC; Haseman JK; He H; Zheng X; Majstoravich S; Korach KS; Dixon D Toxicol Appl Pharmacol; 2005 Dec; 209(3):226-35. PubMed ID: 15922381 [TBL] [Abstract][Full Text] [Related]
16. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. Black LJ; Sato M; Rowley ER; Magee DE; Bekele A; Williams DC; Cullinan GJ; Bendele R; Kauffman RF; Bensch WR J Clin Invest; 1994 Jan; 93(1):63-9. PubMed ID: 8282823 [TBL] [Abstract][Full Text] [Related]
17. Changes in 5-HT1A receptor binding and G-protein activation in the rat brain after estrogen treatment: comparison with tamoxifen and raloxifene. Le Saux M; Di Paolo T J Psychiatry Neurosci; 2005 Mar; 30(2):110-7. PubMed ID: 15798786 [TBL] [Abstract][Full Text] [Related]
18. Characterization of the pharmacologic profile of a standardized soy extract in the ovariectomized rat model of menopause: effects on bone, uterus, and lipid profile. Gallo D; Zannoni GF; Apollonio P; Martinelli E; Ferlini C; Passetti G; Riva A; Morazzoni P; Bombardelli E; Scambia G Menopause; 2005; 12(5):589-600. PubMed ID: 16145313 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice. Gutman M; Couillard S; Roy J; Labrie F; Candas B; Labrie C Int J Cancer; 2002 May; 99(2):273-8. PubMed ID: 11979444 [TBL] [Abstract][Full Text] [Related]